The B2B2C platform helps healthcare providers, wellness brands, and clinical programs deliver personalized, science-backed meals to support disease prevention and treatment
Mealogic, a B2B2C meal delivery platform transforming the Food as Medicine movement, has raised $16 million to fuel its next phase of growth. The round, led by S2G Investments with participation from Dohmen Company Foundation, U.S. Venture Partners, and Unilever Ventures, will help Mealogic expand access to its science-backed, turnkey meal delivery solution for healthcare providers, wellness brands, and clinical programs.
Unlike consumer meal services, Mealogic operates as a white-label platform, enabling partners to deliver chef-crafted, nutrition-forward meals under their own brand, whether targeting metabolic health, GLP-1 support, anti-inflammatory protocols, or other diet-driven care programs. Partners can choose from 5,000 nutritionally profiled meals and more than 25 dietary protocols, with Mealogic managing everything from e-commerce to food production, delivery, and customer support.
“With more than 40 clients already on board, we’re helping advance both prevention and treatment for diet-related health challenges,” said Derek Mansfield, CEO of Mealogic. “Our partners can focus on growth and care while we handle the operational complexity.”
Investors say Mealogic sits at a critical intersection of healthcare and food systems transformation. “At a time when chronic conditions are surging, Mealogic offers providers a scalable, effective way to drive better outcomes through nutrition,” said Dan Ripma, Vice President at S2G Investments.
With chronic disease on the rise and healthcare costs climbing, platforms like Mealogic are helping healthcare systems, employers, and wellness brands turn food into a powerful tool for better health—and new revenue.
